Trials / Completed
CompletedNCT03746301
Xarelto on Prevention of Stroke and Non-Central Nervous Systemic Embolism in Renally Impaired Korean Patients With Non-valvular Atrial Fibrillation
Xarelto® on Prevention of Stroke and Non-Central Nervous Systemic (CNS) Embolism in Renally Impaired Korean Patients With Non-valvular Atrial Fibrillation (NVAF)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 924 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the safety and effectiveness of Xarelto in renally impaired patients with NVAF under routine practice conditions. The information collected in the XARENAL study will help to understand how renally impared patients with NVAF are treated in the real-world setting and what the outcome for the patients is under those conditions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rivaroxaban(Xarelto,BAY 59-7939) | 10mg, 15mg and 20 mg film-coated tablets |
Timeline
- Start date
- 2018-12-03
- Primary completion
- 2021-07-28
- Completion
- 2021-12-15
- First posted
- 2018-11-19
- Last updated
- 2022-12-08
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03746301. Inclusion in this directory is not an endorsement.